0001193125-13-146083.txt : 20130408 0001193125-13-146083.hdr.sgml : 20130408 20130408170037 ACCESSION NUMBER: 0001193125-13-146083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130403 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130408 DATE AS OF CHANGE: 20130408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 13748889 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 d518287d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): April 3, 2013

 

 

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   1-1136   22-0790350

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)             On April 3, 2013, Elliott Sigal notified Bristol-Myers Squibb Company (the “Company”) that he will retire from his position as Executive Vice President and Chief Scientific Officer and as a member of the Board of Directors of the Company effective June 30, 2013.

(c)             On April 7, 2013, the Company announced that Francis Cuss, Senior Vice President, Research, will be promoted to Executive Vice President and Chief Scientific Officer, effective July 1, 2013.

Dr. Cuss, 58, joined the Company in 2003 as Senior Vice President, Drug Discovery. From 2006 to 2010 he served as Senior Vice President, Discovery and Exploratory Clinical Research, and since 2010, he has served as Senior Vice President, Research.

There are no arrangements or understandings between Dr. Cuss and any other persons pursuant to which he was selected as an officer. There are no related party transactions between the Company and Dr. Cuss.

Effective July 1, 2013, and in connection with Dr. Cuss’s promotion to Executive Vice President and Chief Scientific Officer, Dr. Cuss will receive the following compensation:

 

  •  

An annual base salary of $875,000;

 

  •  

An annual discretionary incentive payout under the Company’s Senior Executive Performance Incentive Plan or any successor annual bonus plan based on a target bonus opportunity of 100% of his base salary based on the attainment of one or more pre-established performance goals established by the Board or a Board Committee;

 

  •  

A long-term performance award valued at $500,000 on the first business day of the month following his becoming Executive Vice President and Chief Scientific Officer. The terms and conditions of the award will be substantially similar to the Company’s standard form of Restricted Stock Units Agreement with five-year vesting under its 2012 Stock Award and Incentive Plan (“2012 Plan”);

 

  •  

Participation in the standard annual long-term incentive award program, including eligibility to receive grants of performance share units and market share units, the terms of which will be based on the Company’s standard forms of equity award agreements under the 2012 Plan; and

 

  •  

Change-in-control and severance benefits in the event of involuntary termination without cause in the same form as provided to the Named Executive Officers of the Company.

A copy of the press release announcing Dr. Sigal’s retirement effective June 30, 2013 and Dr. Cuss’s appointment as Executive Vice President and Chief Scientific Officer effective July 1, 2013 is attached to this report as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

99.1

    Press release dated April 7, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BRISTOL-MYERS SQUIBB COMPANY
Dated: April 8, 2013   By:  

/s/ Sandra Leung

  Name:   Sandra Leung
  Title:   General Counsel and Corporate Secretary

EXHIBIT INDEX

 

Exhibit

No.

   

Description

99.1

    Press release dated April 7, 2013.
 EX-99.1 2 d518287dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Bristol-Myers Squibb Announces Appointment of Francis Cuss as Executive Vice President and Chief Scientific Officer, Effective July 1; Elliott Sigal Plans to Retire

(NEW YORK, April 7, 2013) – Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of Francis Cuss, MB BChir, FRCP, 58, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., 61, retires. Dr. Sigal has served as the company’s chief scientific officer since 2004 and on the company’s Board of Directors since 2011. He will retire from both positions effective June 30, 2013. Drs. Sigal and Cuss will continue to work together until that time.

“Francis is a strong and collaborative leader with broad experience in both discovery and development,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “He has been a key member of our productive R&D team who, under Elliott’s leadership, has delivered our strong portfolio and pipeline. As our company embarks on the next phase of pipeline execution, this is a natural time for Francis to lead our R&D team. Having worked closely with Francis since 2010 when I invited him to join my Senior Management Team immediately after becoming CEO, I know that he can ensure the continuation of both the leadership and strategy that have been the hallmarks of our success.”

“Elliott has been a key leader in the development and execution of our company’s strategy to become a BioPharma leader,” said Andreotti. “He and his team have become one of the most productive and innovative R&D organizations in the industry. Elliott has had a significant impact on the transformation of our company and, most importantly, on the patients we serve. I am grateful for the many things that Elliott and I have been able to accomplish together.”

“I am honored to have the opportunity to lead this talented R&D team to fulfill our mission and find new ways to discover, develop and deliver innovative medicines for patients with unmet medical needs,” said Cuss.

Dr. Cuss has a strong medical background, and broad experience in both research and development. Prior to joining Bristol-Myers Squibb, Dr. Cuss led teams in the successful development and approval of several blockbuster medicines. At Bristol-Myers Squibb, Dr. Cuss

has a proven track record of leading our company’s research organization to become among the most efficient in the industry. He has built a high-performing team, and has delivered a differentiated and innovative early and mid-stage pipeline including making significant contributions in the advancement of our company’s Hepatitis C and immuno-oncology portfolios, particularly PD-1.

Dr. Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. Under Dr. Cuss’ leadership, Bristol-Myers Squibb has consistently been rated a leading research organization based on cycle time, success rates and costs, having increased discovery output while maintaining a flat operating budget. Dr. Cuss and his team successfully integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. Dr. Cuss became a member of the company’s Senior Management Team in 2010. Prior to joining Bristol-Myers Squibb, Dr. Cuss spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe.

Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr. Cuss received his medical training in the U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine.

Dr. Sigal joined Bristol-Myers Squibb in 1997 as vice president of the newly created department of Applied Genomics. He served as senior vice president, Early Discovery and Applied Technology, head of Drug Discovery & Exploratory Development, and senior vice president, Global Clinical and Pharmaceutical Development, before being appointed chief scientific officer and president of R&D in 2004. Dr. Sigal has been a member of the company’s senior management team since 2001, was appointed executive vice president in 2006 and was elected to the Board of Directors in 2011.

As a physician, Dr. Sigal’s commitment has always been to the patients who have and will benefit from the new medicines he and his team have helped the company deliver. Under Dr. Sigal’s leadership, 14 new products have been brought to market including medicines to treat diseases including cancer, serious mental illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, solid organ transplant rejection, and cardiovascular and metabolic diseases.

There will be a conference call on April 8, 2013, at 9 a.m. (EDT) when company executives will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast at http://investor.bms.com or by dialing 913-312-0389, confirmation code 6437563. A replay of the call will be available beginning at noon (EDT) on April 8 through noon (EDT) on April 23, 2013. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013, confirmation code: 6437563.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:

Bristol-Myers Squibb

Media: Jennifer Fron Mauer, 609-252-6579

jennifer.mauer@bms.com

or

Investors: John Elicker, 609-252-4611

john.elicker@bms.com

GRAPHIC 3 g518287g59r74.jpg GRAPHIC begin 644 g518287g59r74.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`*P#A`P$1``(1`0,1`?_$`*@``0`#``,!`0$````` M```````'"`D$!08#`@H!`0`#``,!`0`````````````%!@!F,VB,`8UY- M,Y$V1M@;CMILQV<\HF`W)J/.2#.UE.JH8"!]Y6_Y*[_`)(_#WMQ M0,4<&AFE\Y&&.;\#G[.E-HA-(2#@+,<`R`3/)HY@ATF`^7D(@(AZ@'?ISBCQ M#)*YNZW4>]OD1[?+QC[JLZQBCK/D:VL`?]?T_=%H.5Z+;#B$.(0XA#B$.(0X MA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$9T;)$B=G M(.*$XS&C%J.M9_7T:-[KG)-K9+[3?9O&P?$P,4J9E"0J-J>"8@7_`.QGY@&_ M,W>M]Q9]=9WAMN'YW7MDDT8DD\W.&@W2`4`F,OS%E#=075X2QV\S\S_8)<(A MF/X#A56195;)2!^AEIP?.;'JOINP8K2/[^JU]>V*.&4?F)9-*+R!.)$?C@!C M%`K,42B7TP/S3M61>/DKQS`MA<=KFZAK@"2I0%#HI0'TD#U3K=#R6X_RZRS< MHK?;>`0=%!1/VI[](\E9T(@4]3OE]6+BY-1TK#),PY\LE3N=X=++M=5F*F`/ M[V_@=22))J'*4S9UXE`<$[7T1P'J2M%RK+(VBM_*(Z[(6(I9D^=YG,8^,@*HVA.8 MR_Q*/L3$J=G`H.?LJA1$>@)ZOYWQ;.^YF9U-XY=EH[+;V6P@#<2255`4U7CIXA`)7:^/W;X-V=?TK8S MX6$`E+%,I/7D\BIOR^G7K2^X^''M] ME!L+ZK>T-!X3\M=5"K(3'MC0>V&=_P!0<9%^^4-OF9?:O#]HXQ+5[W++*?+5 MA(C1EA7.-A6C%Z\>P@?LP!6S$^G$%9[)?U!?']K1@OJKXAZ>7\7J`C!V*PTE MV^:^;KFT!#%!<%).DB-/,^K732)_)L@K;&:3Y*B=<#6\Q"A1.,Y<=?Q58LYR M"BT17BO=A:NM&SKII^'NN2X337YQB#+96,9L=<)L:W6;,@OC$W(.ZZ9,=X.I MBB(G!/L"^7T'U[EKGC5YM%HHKQ<`UK+B"6SF@0*GA,:$R(7:2D5JU9+9[K=Z MRRT!)?;B`Z4I_7]//6+#\B8LL9Y:Q[56'Z&J/,ZFUQT MD"U!M*Z*245=#.49=B&:7?(,RO.+UU(&-MI`$]57QUA\BNS%MZA:ZO=\U?$( M+/BP]V8<:41>6YSU@9[BW25]8XVT)Q\&$JHG?AD#V3T,42B4P=!W].CMEC%F MS?)QBUYK',+Q(M`606:@@2&I":"11>_NIF%WPG&3DEFI`\@H=V@!\4FFOB== M8E[7O9^O+_UHAFS[&Y8C%#'V&&E$A]PR2@G#C,(*$G32\&(!Q36B>2UYB:@F M_P!@FZ`!`>1>3XS78[DM7C'/&YS'D`^*_#P&H(!1`J\(G,8S"S9#B%)DUO)% MF@\N7?N?VZM/;NCH6\RL>^^W)I)D-HVH/\RN/P M@EQEPBA=JNY]U[D5M811MM]BMX`XZE3MGX#5):HJ1L%S(XVN'$(<0AQ",YOD M*W'S--:LA,BC,-:YI8-L6E$ZAKW$D;P,9A+;)9,9<$'><2`IO/%C6,5,?(2! MV(B'KZ=50._JVH&34W8&%*2/%FT.A9G ME!):R,RKRPM4B8YVHL+7',H&\03A>P M00VX[`"U9EH:J<4'I]0F$*QQ:;EW.HLCH[=D])9C9:U0#;]Y1R$A2Z9]QDH6 M21IES/HU2'$(K1L;<0>0=CZ@89S&[+17^N^2KJYEMY8:3N=,?>!I,S'L14K63WRM ML-!\Y0T3K@\G1O[N/LB`JVVFGD$R8^(P%`2]$;Q`ZOT-Y&#D_=L2HZ3`+?FE'5%PN3R-$V[0Z4L%U[&5S1\G>9#)7!O=HL,_>12QLYC82XY22!0Z"&68I/=$@3,3H`$O7';_ M``ZCRX7IU;5EHM=F=<."$-*'ZM"FOU1Y^XF;W3#'69EOI`\W*\MM_P#Q*0?K M0C]ZC1'E$C5(<0B"K]<9@QT[:#K7P9H39N@$KSXT5G:P>W11Y39 M)*``+P`&B14L@+OG@VO/3, M]JCD]S&:,&9$Q=U2B[L=5IV6I&T"?F[!Y3,[*`<``I@[Z&*RT6.DKOY^M?;2 M?\+220)H2T$A%43&IB;PPWJIH2ZCHVW%H\2`GOE'N8\\6]&]BZ68F&*L46$9 MV]M$P@E:92$TC+*T/[&?(FB#^HK9*:5<)IF9`="-;44W7MV`)FPQNQ&&-%8J MC$JVMW\QY#@`[F`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`E./)[I%)F]CPC%:ND: MWEUXN*EH(,MI`;.32B$3]/IUG%8ZU6X'?.X&3T-6'.H.FA"09DD>KS1=?;I* M+B;)N6R>AU`53MV;9^T[J?FR4U?A[`5]8)X9FUG/6B>96,60$@K-'(HB-=_M MI=W,+,5G,*9B)@4X'*;UI6)4V,]PLIK\)Y-F9;N6KA;G-/J#FHT!VI>2`5)( M+2T-(=J+UE_.S#MIC-#FK[Q>+DX$=0:40M<)E"@:`9:I-5&@])K]:D9I[=?Y M@;/E6+(LF+QZ4ZG9N82)QMZFQ#Z``_. M56NLN_;W#+'1`%_YDDTX@G@?#P7S&L=V'WJCQ_N'GU]KE#`ZVDRU&US9?61' M?[G[0UMLMIM.<^M<.P\="(7GJC@O9[%J:=UGY@^[%UL4HL"-E1N(`_"`%'OQ M[#U#OGDP##KWB>;4G4@T$V6YHA)*"W.,U$I$>,S[(]7<3+K/EF`571'$AEXM MP/!3U)L^.NT_13%=/[>;HK7;ZY/C\A;&Z?V9[@2)JV59C616W-JWMA1N:<)R(BOFI(;+J`#B3(#:W:=J#9M52D04+$; MUS$/FASM7IT^UE;,"VI=Y+`,:(X+"XM;[["I8WVH2++)8P)"`JP(_;`/$1,J M8G0>GK,7^MLE+_3_`/55&+A8>B(A*$$HFAU5P$CQD>$0N-T63-;G@PZJ=;[U M0WI0FA:'.!UW)\)`)&HF#J;/S#=E[E].41L'45FV&HQU7IW*=E[YB7WX0<)> M[1_%/'X'5L[,G$E!QY)+;L870KX9K,R^3-'W`H"`&*7E-IL`I*.\5N*7BA&Z MXWT6VW..FNYQFO\`MQ);-R./@#%PJ^X5566:AR6S5@)M]E-QN(`UD0![3<0A M\1IK'A*2LW;:RW[5.34U?EJW#=$T=*_L_<:.29ECS3IY6U,6$Q!*#0S&!.*@ M:-6<2-O>"9A;&AY>'_R3,H[`!``XRMYMV'V[D7FDO5#T['@"+ITY-2 M/::UXV\E^6=N?E8^YTTQ5-7=G;"@5=P4(?6+?&)\=B8#&8&.>B$.$S'%U3EP M`$S69,1$5?H/';)8PRQ,(N=E!D`0$).2+Z0@TF(X/QZWC84KN>*51>]_;#P#:V"M,Y_KUK5?S;' ME8/;QLMO.LTSVAG>/1_"1C\9BA0(8G@HH=1H,(_;/U[B?L[KV*CI+%UK&:&R M/P/_`&ZX6WB`0HN*ZG@/`I[([^U][K*S):6RWZ]7L9HGYA;[E/XMQ:;I$3<=>-IM8JDVYJ%UH^Z&P7*./AB9[7EX.;^AD+$]-'9V=_CRYBB8CW MB>7D!NNNNP$/IUBN'Y->\*O0OEC*.&HX$>!_`ZCW@[7F&(67-;,<8O7PG3RX M+[/[8QGK2_=E_B_N5OU*V6E&7L90LPKVP9%JU;^6UD/_,\3&PO$WB8Y0VVZXQB_=BR?KC$6B@OX>.H6\`?WB%>THA"$N4: MS:1NUPBV93EO:.[#"\I::ZQEO\A7DKPD)DD:@.:22/B:2UR-ANRY[MG(?BS> MOD+<-O;HCEKV`F@^8=:PG(@S5444KV:VLA!L>&QM@-%?W29]Q(ZN'B]`\B]$ M7$0`0,40&[QU_;NVAP%O3<6_`B!LOB4HLQQC0VC+*O&2_(!M'03O=4@=H/%M5* MEE=:8&6Q,0!`G:?"9$'U3S+YR*1$.83"+L(B8`Z_@$W><7VTXO3=O;3D+*%H MYCKTYIX%P;N`:7!2`HE(I-`28U'&[GDE5W,N^+U]7NLC;.TCR4@!P\"`225T M\$G0AMVSVRR?C6H2]%[^D6)8D@WD_I9/'8&"$@YS"'N]W2*+BQ^D7$D;!--J M`H`S@`^)A`.P[ZT1^%X0[NC5V-U$MB;92X:R*(LM9%(RZDSC,JSM'1WWK`Z\ M;T&DH)B9`]FI32+7GKO+M/Y=]LXQBV%8U8'-J'2F4,CJYX9(W)R=2`I09SO6 M5'9&/@7Z^G0_[0,'7*9SKGTGLG9*L4G*KAUJX?&W7XHB4/EMZ6Q=]#T3"+AF>7-9UKS\SM>:ZA9PXC&VN< MP:8V,C!DD+V`@$7_`'*/F`'Z'Q[`/3L1$=/I+!8\=RBLKK'1CH%RP\AQBCH[W6)D%NS?II*:HOOX^Z-4:9L"R:7^1V2Z;/%H6);]: MS34]JV/C+_9J["]R6#2Q.T7ZO7MC0=X['8T1:.28K3[D0JG?2Q1`H%`W,2NU MLH+_`-JOUW3T;*&]\N\FWNV@[2W9N"-)/!"/4=%":1M=BNEZL/=<8`:PUU@? M9NH#/AXX)#$ON*U-?5%M?1$_Q6 M@@H0CB!^7%"D]P13,(`4#C&49/3T%./DJQ"QTP=)$K`3F$P?KQ#KKQ*3-#OKH.6C^;M MPZ%Z@P3N9)'%4!)G[#KH/&*N/E:OYN]D;BB6VW::<0!)25\M>*1PI'EUY%<* MT(1B93>_U9-HW,+`UVE33G@UA`9^PLO_`'40CCZ7RE+#(U2D`Q1`0\0'#*/Y M\\2AQ26O&0,=MN0DC@2-KY<$XR1'!)1]5(M%&RKH7[>A.`-N]H$P M..OOD?"+U4=%H^ZYKE84>9FAEAV-C.<.J)D:L4F"VI1$'KSD4Q23+Y^!K/D+ M*D<@@7H[*W8!OJ81&@7[GUM+S/D+FO700ZO)3XT,@$1&@*JE7$Z)&FXU34CV MB\6_;T+2@"Z-(F5UF=%`E%K54ONI"F`BGWUZEZ].OP``'KKE:BX1C?5GQNW7 MKQ(+MSZ!WCD\9P;^E;G.)B-DTM"[.E#?*A*Z=^0M(D' MQ#L`,!!-L%Q[HV'(*&@Y646,.-M9M"5[VM0HH3:0UI02).@$TC"+#VIRC%:F MMYF,Y(6=0F5MS2>,U#D**BR]BK''<_B)@:>O$7H6O[EET2-C7BS;&638CO&V M::3>U[29$<4S2]R161J&1:2HJ@!OT)"^'B;Q#KHPG^J3O)=&Y,Z_5M(Q[C9N MG-"EH#)C;(A]OXV4TUNRN2DJL:#E\V%V%%W?E2,4>(97+$S:`F\ON^J M@@0.ZKB&5TN*NK7.=8-)YWBD";?OM.% M,MK%D:8LL<3R"_;*4&43E*/8"'?7+':^Y]+CU0E`>>>F[LU]MM%DH:*B;^H<;!%ON)<5:'&0+`K24&I,IEJ@D1[>;VBH MJB^7FX55:X6'(D-PMX$B1,%KN`4^\3X&/EF_'E-;(P*AK39':"27A0M(OL>D MK'6)ZU984[SMR@0)JP$EJ3Z/R40E",6''(*I46EH!W,4#*AV`]?`[F4=KK*R MY8E9V6V]W$'_`+FXN+02-R*T@*@DNT$#TN`2.'=K>?=J6CLF57AUPLEN,F(F MZ2@5\W;@!I-4U*J8G"@]09#26R.R.P6=/Y/>,H-:7&YE2$1$T^GU3CV&XVM+[M=6#=5[7;KO3[2K,(E M+GO-98BQ2=R?A@LA892PXZ82'Q(S#CR-DQ#>1`$PE+]![YU8+E-)A%Y%^-"+ MAS1P+B!]:`C0&:'3VQ[\\Q"KS:R&RMK30-/$`'\0>/"+.,38^8D4PFURD(.< MDQVD,++E'M">`&8Y`B5,SI[(4YL`&$OX=]#Z5.H=3FK)(2>B_CI]$B MWTU-4T]'\H2"[QC-W6[49/1B4;+W_/=FW M]QFZ+VP_9,TX*:>;G`=O*04OS@/J/H.EY1EP[B4%FQ.BLP#[:-M!M:Z@0@%$O MOYNC#_ZR7='+;[2Y70T3JHOOV-HU2@2XJ'/TGW$3"B4J:TKN*G(G':<9=S)VMKY!'!J&,Q'&KZ&8-P M8,78'9!\:(0YWBF4RIHHB<01$I6%-],U!X>Y@)A-R$O6?6*[5)OILK>ON0N. MXGEDH&_Z`@-(0#VG4+K-V3`,BL-'TBCO3N@@$AH9MN@`!'FACY0?1&9?UWIN_[YV+S+ZEFOL1E47J10*Y9:^< MDU)1'R1]^?)^\LDBRT9V_+I)AT*:32B!C&.)>_(17+.Z9F-5^+8U0MMG+N)W M$[W/*A"$!:$`D9(G`36.;7VYJG9-19-E%W=8X;59764- M=0UIMUYMY)!`74>WQ^]/*(58-`)!*[NC=_[97YG;.R>NX=+X;6,54K5CJZLX MFVSMI/'9@\GCC!ER]"`O]Z,V_ MD!U@D.G'QNW;56#LUF2.@,'+BS94=,RR&Q/`F[;[Y=\7DY&0EMA(O?Y*,7Q\ MG,5+_P!0"@D'U`?`>M9[6Y/39GW/H+XZS,.2$`ON0>Y`=I`(800%(1"DIJXB M>0]U\/Y^!]JJ^QLO)-C!`H+?M"_^P:_XOB<`'+X2FBQI%DZ((3X9DE9"0+9+&K/P>JO%X.<8M=W6]UQLX M:FUI&@(=,R3WJ"1PB'$?B.S&G6J(ZQ->TAWZE_571F=:Z+T]=Y(VH/5-J M#02!3CNXQ#,['\NDQ&CPRAN[A9K?>>H+MF0-R-UD`I,_'0Z1*SUH3=39LQ+] MJ:IW%=(18EB5ZQUA+<63TA#9U&"LL>Q^T#QIH-)X>,;,,A\G$PK"ZB<1,41$ MIO6%I^Y%F=C-%BM\LAYEEMY+F_S[VB9)5=I1R%"?%9!4B7YO;'(N1EE;FEEO M(Y5[KF@%;>#)``"2[0)J0OF91XR7_$]'%J+J"J:UORP:]?ZPO'^YW/GN='8E M,W2R[Z(B0$YQ.VG(Q\=`^0!Q]$VPZ`%*/X]>LA2=YK@Z]5U[JZ1I%PLW3'`$ M#;;Y*S0J3JIVE2A\O)<>RU`_&Z*RV6K-"ZWW@7)I*G\P`1KE#@FT2`)(`X'2 M+243JT\5W;DRV)N2SOZVWU-H6U5>G+\2&MM;L$,K!B=U'[%A<1@C8_R@,4II M0^9K@[N"CJL=58Q`*`%3'NBWS+&UEHI,9LU"RW6-KM^T$N<7H1N M,14@UB-`.\?,Z-3YCIDRAP\W"=X^ZI/+([-*Z93`DLCD)AT?L/0/'KZ]>^QW MROL%:*^W%'A>"JO`A1]A'X1"7ZPV;(:+I]Z"@_5]/MB'ZVU79:F:D6B"6E;+ M.B;H5X[_\`I^XQYR;Z+53:CN5ULZ4V),?N&'WG M#RG2)Q=MEWFSBQ@$E3KV*PXSUUCF#^,0Z-Z=`'0NA M\?,Z)PX>R4>"[=LK'=ZSYZ\3=X2\/I[?MBZ#?@-[1@8;=@8N,WM[=BEQ<3$Q MB@3#P\%(I2D(4/$I2D*1,`#_`,CRC<8T>7)'@([CG$LK%R\0N?A99!Z[*9-0#)G`!*'U`0_P`. M?,J?Q!$.-C8_H`%`![`"^@=!Y#Z?X\^HXCG<0AQ"' M$(<0AQ"/./;"QOR"*#VTMKNACB&3C(.>$FX`0X!_&4JQ5"^7KU^/?.WD5%72 MA:,ELD4%(\U32TE4@K`"V.;A86`V8B6"VX>-@8.*3QQ<3$Q"86%BD*!O0J:9 M2)E*/E]"@'^7X\Z^,>B7('E';